Skip to main content
Download PDF

The associations of oxidative stress and inflammatory markers with obesity in Iranian population: MASHAD cohort study

BMC Endocrine Disorders volume 24, Article number: 56 (2024) Cite this article

Abstract

Background

Low-grade inflammation and stress oxidative condition play a role in the pathogenesis of obesity, and the serum levels of these markers, such as pro-oxidant-antioxidant balance (PAB), high-sensitivity C-reactive protein (hs-CRP), and uric acid may indicate obesity progression. In this study, we aimed to investigate the relationship between obesity with PAB, hs-CRP, and uric acid in the Iranian population.

Methods

This study was derived from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study. A total of 7985 subjects aged 35 to 65 years were divided into three groups according to body mass index (BMI) as: normal, overweight and obese groups. Anthropometric indices and biochemical parameters such as PAB, superoxide dismutase type 1 (SOD1), hs-CRP, and uric acid were measured in all the participants. We evaluated the association of obesity with inflammatory factors by using multivariate regression analysis. Also, those participants with hypertension, an endocrine disorder, history of cardiovascular diseases and diabetes mellitus were excluded from the study.

Results

There was a positive significant correlation between BMI and serum PAB, hs-CRP and uric acid (p < 0.001). While no statistically significant relation was observed between BMI and SOD1 (p = 0.85). Multivariate regression analysis showed that the risk of overweight and obesity increased 1.02 and 1.03-fold according to increase 10 units of PAB raise in comparison to reference group (normal weight) [(odds ratio (OR): 1.02, 95% CI (1.01–1.03)] and [OR: 1.03, 95% CI (1.01–1.04)], respectively). In addition, hs-CRP serum concentration was significantly associated with a high risk of obesity [(OR: 1.02; 95% CI (1.01–1.03)]. While the high levels of serum uric acid were associated with increased odds of overweight and obesity risk [OR: 1.4; CI (1.39–1.58) and OR: 1.76; CI (1.63–1.89), respectively].

Conclusions

Generally, we showed a significant association between BMI and serum PAB, hs-CRP values and uric acid levels, suggesting the role of these factors as risk stratification factors for obesity.

Peer Review reports

Background

Obesity is an important public health challenge worldwide [1] and is related to several disorders including hypertension [2], diabetes [2, 3], cancer [4], and cardiovascular problems [1, 5]. In 2016, the prevalence of obesity was estimated at approximately 650 million adults, 340 million adolescents and 39 million children [6]. A recent systematic review and meta-analysis study indicated that 35.09% of Iranian population are overweight or obese, that was estimated to be 56.55% for people aged over 18 years and 21.11% for people aged ≤ 18 years [7]. Although public knowledge about the harmful effects of obesity has increased in recent years, the mortality rate of this chronic disease is increasing globally [8]. Some risk factors involved in the development of obesity are genetic factors, lifestyle choices and medical conditions [9,10,11]. Pro-oxidant-antioxidant balance (PAB) is a measure of the status of oxidative stress [12]. Oxidative stress is defined as a condition of imbalance between pro-oxidant and antioxidant production which results in increased reactive oxygen species in tissues [13]. This condition has a major role in the incidence of various diseases such as cardiovascular events [14], diabetes [15] and asthma [16]. The relationship between obesity and oxidative stress is well established; a high consumption of fat and carbohydrates in obese subjects may be associated with an increase in oxidative stress and inflammation [17]. Prolonged obesity is associated with a reduction in the serum activity of antioxidant enzyme including superoxide dismutase type 1 (SOD1) and glutathione peroxidase (GPx) [18]. Moreover, there is an association between high levels of serum cholesterol and serum thiobarbituric acid reactive substances (TBARS) with reduced serum anti-oxidants enzymes activities in obese subjects [18].

Prior studies have shown a positive correlation between obesity and the level of high sensitive C-reactive protein (hs-CRP) [19, 20]. It has been reported that oxidative stress has the ability to affect serum hs-CRP and also increases inflammatory processes and markers of atherosclerosis. On the other hand, serum uric acid is associated with oxidative stress [21]. Several studies revealed that serum uric acid has a role in protecting the body from oxidative damage [22, 23]. A positive relationship between serum uric acid and obesity has been previously shown [24,25,26]. Although there are ample of evidence about the association of body mass index (BMI) and inflammatory/ oxidative stress, up to date, no prior study evaluated these association in a large sample of Iranian general population. Thus, the main aim of the current study is to investigate the association of obesity with biomarkers of stress oxidative and inflammation in Iranian adult population.

Methods

Study population

This study was performed on the population of Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) cohort study. The MASHAD study was started in 2010 and consists of 9704 participants aged 35–65 years, who were drawn from the north-Khorasan Iran, by a stratified cluster random sampling method (code number: 85,134) [27].

In the current study, we recruited the number of 7985 individuals aged mean 48.68 ± 7.89 years including 3282 men and 4703 women. We excluded all individuals with hypertension, an endocrine disorder, signs of cardiovascular diseases (CVDs) and diabetes mellitus. The same equipment and methods in clinical and laboratory indices were used among participated subjects. Both men and women were divided into four groups according to body mass index (BMI): (a) underweight group; BMI < 18.5 Kg/m2, (b) normal group; BMI 18.5–25 Kg/m2, (c) overweight group; BMI 25–30 and (d) obese group; BMI > 30 Kg/m2 [28]. Participants provided written informed consent to participate in this study, the protocol was previously approved by the Mashhad University of Medical Sciences Ethics Committee. Also, the variable data as past and/or current smoking status, physical activity in daily-time, health behaviors and consumed medications by subjects were obtained by standard questionnaire interviews [27]. The acquired information was recorded and organized to consequence analysis.

Blood sampling, blood pressure and anthropometric measurements

Blood samples were collected from each participant after 12–14 h fasting into Vacutainer® tubes. The samples were centrifuged for 15 min at 5,000 g to separate the serum which then was aliquoted and kept frozen at -80o C for analysis. Blood pressure (mmHg) was measured twice with each subject being requested to sit and rest for 30 min before each measurement. The two systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded and the average was used for the analysis. Height, hip and waist circumference were measured to the nearest 0.1 cm, and weight was measured to the nearest 0.1 Kg without shoes, in fasting state for all individuals, then, BMI was calculated as weight (Kg)/height2 (m2) [27, 29].

Physical activity level (PAL) determined using the modified standardized questionnaire of the SHHS / MONICA the questionnaire. Questionnaire is about the time the subject spent on activities during work and during the non-work time, as well as resting in bed and sleep. Individuals with 1-1.39 physical activity the level were classified in the inactive group, those who had PAL between 1.4 and 1.59 and 1.6–1.89 were categorized in low activity and moderate activity groups respectively. The PAL of high activity subjects was 1.9–2.5 [30].

Biochemical analysis and quality control

Lipid profile including serum triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol and fasting blood glucose (FBG) (mg/dL) were measured as previously reported [27]. The level of serum uric acid (μg/dL) was measured using Pars Azmoon kits on a BT-3000 auto analyzer (Biotechnical, Rome, Italy). Serum hs-CRP levels (mg/L) were determined by polyethylene glycol (PEG-)-enhanced immunoturbidimetry using an Alcyon analyzer (Abbott, Chicago, IL, USA), as described previously [31, 32]. Assayed serum controls at two different concentrations were used to monitor the quality of assays. Intra- and inter-assay coefficients of variation (CV) were both 4.0% for TG, 2.0% for TC, 5% for HDL-C and LDL-C, 2% for FSG, 2.0% for uric acid and 17.0% for hs-CRP.

To SOD1 assessment, at first diethylenetriamine pent acetic acid (DTPA) (0.001 M) was added 0.05 M Tris (including 0.001 M DTPA) tocacodylic acid 0.05 M (comprising 0.001 M DTPA) to make Tris-cacodylic acid buffer 0.05 M (pH 8.2) which was then air-balanced for 1 h. Pyrogallol solution (0.02 M) was produced in water which leads to eliminating the soluble oxygen and then was aliquoted and froze until analyzes. Then 20 μl of sample or control was added to wells in duplicate. 0.02 M of pyrogallol stock solution was diluted 1:100 and then 180 μl of the solution was added per well. An enzyme-linked immunosorbent assay (ELISA) reader at 405 nm read the mixture for 1 h at a distance of 5 min. The activity of SOD1 was calculated by the level of SOD1 which inhibited the oxidation of pyrogenallol by 50% compared to control.

PAB assay and quality control

The values of serum PAB were determined and validated as described, previously [14, 33, 34]. Peroxidase enzyme (Applichem, A3791, chemicals used were reagent grade and were collected in double distilled water [35].

3mM uric acid (in 10 mM NaOH) was added into various proportions (0–100%) of 250 μM hydrogen peroxide to prepar the standard solutions. 60 mg of the powder TMB was solved in 10 ml DMSO. TMB/DMSO (400 ml) was added to 20 ml acetoacetate buffer 0.05 M (pH 4.5) after than 70 mL of fresh chloramine T 100 mM was used and the mixture was thoroughly mixed to prepare TMB cation. This mixture was incubated for 2 h at room temperature in the dark place. Then 20 ml of TMB cation and 25 U of peroxidase enzyme solution were mixed which aliquoted in 1 ml and kept at – 20 C. Also, mixing 200 μL of TMB/DMSO with 10 ml acetate buffer 0.05 M (pH 5.8) prepared TMB solution. 1 mL TMB cation into 10 mL TMB solution made the working solution which incubated 2 min at the room temperature in a dark place. Then, 10 ml of standard or any sample was mixed with 200 μL of working solution which then incubated for 12 min in a dark place at 37 oC. Ultimately, in each well of 96 plates well, 100 μL of HCL (2 M) was plated to measure the absorption of the samples using an ELISA reader at 450 nm with a reference wavelength of 620–570 nm. The standard sample for every plate presented the standard curve which used to investigate the amounts of serum samples [36].

For the determination of the precision of the modified PAB method, the intra- and inter-assay coefficients of variation (%CV) were determined. The %CV of the intra-assay for 28 samples analyzed in triplicate was between 1.4 and 3.5%, with a mean of 2.1%. The %CV of the inter-assay for 20 samples, analyzed over 3 days, was between 4.1 and 8.5%, with a mean of 6.1% [34, 37].

Statistical analysis

The normality of distribution was assessed using the Kolmogorov-Smirnov test. Quantitative data were expressed as the mean ± SD for normally distributed variables or as the median and IQR for not normally distributed variables. For normally distributed variables, the one-way ANOA test and was used. Kruskal-Wallis test was used for non-normally distributed variables. Qualitative variables compared using the Chi-square test. Pearson correlation was used to find a linear relationship between BMI with serum PAB, SOD1, hs-CRP, and uric acid. The multivariate regression model was used to assay the association of obesity with serum PAB, SOD1, and hs-CRP after adjusting for sex, age, uric acid. P-values less than 0.05 were considered significant for all analyses. All statistical analyses were carried out with SPSS (version 20, Chicago, IL, USA).

Results

The demographic and biochemical characteristics of subjects according to BMI are shown in Table 1 such as waist circumference, hip circumference, weight, SBP, DBP, PAL, FBG, lipid profile, and uric acid levels showed a significant difference between three groups of BMI in both sexes (P < 0.001). While no difference was observed for LDL-C, and SOD1 between obese and overweight men and women compared to normal individuals. The level of PAB in overweight and obese women was significantly higher than women with normal BMI, however, only obese men showed higher PAB levels compared to overweight and normal groups (P < 0.001). Also, the changes in cholesterol levels in three BMI groups were similar in both genders. Furthermore, an increasing trend was observed in the level of TG and hs-CRP in three different BMI groups of both sexes (P < 0.001). Also, the smoking category was assessed for both genders which showed no statistical difference between three BMI groups for women (p = 0.09), while that was different significantly in normal, overweight, and obese men (P < 0.001).

Table 1 Baseline characteristics of the participants
Full size table

Regarding to Table 2, BMI had significantly positive correlation with the values of serum PAB (r = 0.104, P < 0.001), hs-CRP (r = 0.156, P < 0.001), and uric acid (r = 0.134, p < 0.001). While no statistical relation was observed between BMI and SOD1 (p = 0.85). Multivariate regression analysis showed that the risk of overweight and obesity increased 1.02 and 1.03-fold according to increase 10 units of PAB (odds ratio (OR): 1.02, 95% CI (1.01–1.03)) and (OR: 1.03 (95% CI (1.01–1.04)) in comparison to reference group (subjects with normal weight) in Table 3. Also, hs-CRP serum levels were significantly associated with increased odds of overweight and obesity risk (OR: 1.4; CI (1.39–1.58), P < 0.001 and 1.76; CI (1.63–1.89), P < 0.001, respectively) (Table 3).

Table 2 Correlations between BMI and PAB, SOD1, hs-CRP, and uric acid
Full size table
Table 3 Association of obesity with serum PAB, SOD1, hs-CRP, and uric acid
Full size table

Discussion

In the present study, for first time, we explored the relationship between BMI and serum levels of both oxidative stress and inflammatory markers in a large sample of Iranian general population. We found that BMI was significantly associated with serum levels of PAB, hs-CRP, and uric acid. Obesity has become an issue among both rural and urban Iranians [38] and is considered as a reason for metabolic syndrome which is correlated to chronic inflammation in obese individuals [9]. In our previous study, we showed that oxidative stress and inflammation are related to the presence of high body fat percentage with the progression of metabolic syndrome, CVD, and diabetes [39]. In this study we used BMI, because it is a cheaper and more available assessment of obesity than body fat percentage.

In obesity status, adipose tissue accumulates and secrets adipokines [40,41,42] which stimulate the synthesis of pro-inflammatory cytokines and ultimately increase the reactive oxygen species (ROS) generation [43]. ROS production can damage cellular components, leading to inflammation and chronic diseases [44]. An imbalance between production and clearance of ROS (by the antioxidant enzymes), is defined as oxidative stress [45]. The PAB technique can determine the oxidant capacity and assess the status of oxidant/anti-oxidant of a subject in a single assay [46]. Consistent with our results, a study on over-weighted and obese subjects without CVDs, showed that high levels of PAB were observed in obese people (BMI > 30 Kg/m2) with mean 40.8 HK/unit, while there was no significant difference between over-weighted (BMI 25–30 Kg/m2 ) and normal groups with values of 37.5 and 37.2 HK/unit, respectively [47]. Another study among 338 Iranian population showed that lower pro-oxidants consumption is associated with decreased risk of general and central obesity after adjustment for age and sex [48]. It is also indicated that obese subjects had significantly higher concentrations of PAB rather than overweight in male Iranian adults [49]. However, no significant association was reported between oxidative balanced score and any components of metabolic syndrome in a study on 850 adults living in Tehran, Iran [50]. As studies indicated that increased oxidative stress in adipose tissue is a precursor to metabolic syndrome, balancing of the redox status of adipose tissue may hold promise as a potential treatment target for obesity [51].

It is believed that oxidative stress results from not only ROS overproduction, but also can conclude of disruption in antioxidant enzymatic defenses such as SOD1 which converts O2– to H2O2 [52]. Results of a study on mice illustrated that cytosolic SOD1 in obese mice was lower than the lean control group [53]. Nevertheless, in our study, the level of SOD1 showed no statistical difference between normal and obese or overweight groups in both genders. Additionally, no correlation between BMI and SOD1 levels was observed. Although the differences in SOD1 concentrations/activities among individuals may be attributable to variants in genes encoding SOD1 isozymes [54].

We also showed that the levels of uric acid significantly differs between three groups of BMI in both genders (normal, overweight and obese groups). Also, we showed an association between uric acid and a high risk of overweight and obesity (OR: 1.4% and 1.6%, respectively). A similar study on 550 participants indicated that hyperuricemia was significantly related to obesity in north area of Iran (OR 1.92; 95 per cent CI 1.13, 3.23) [55]. It is revealed that serum levels of uric acid was positively correlated with BMI and waist circumference [56, 57] and according to a 10-year follow-up study, BMI increased by increasing the level of uric acid in both sexes [58]. These findings may be explained by the fact that the obese subjects have an elevated levels of plasma free fatty acids in the liver which stimulates the synthesis of triglycerides and in turn may promote the production of uric acid [59]. Moreover, elevated serum uric acid has deleterious effects on the function of endothelium and oxidative metabolism [60].

In obesity, accumulated free fatty acids (FFAs) can cause pathophysiological mechanisms leading to inflammation and increasing the CRP levels [61]. Our analysis showed a considerable change in hs-CRP levels in obese, overweight compared with normal groups in both sexes. Although there was a significant association between BMI and hs-CRP only in the obese group (p < 0.001, OR: 1.02 CI (1.01–1.03)). Similarly, a hospital-based study on 7762 subjects showed that the obese ones have higher levels of hs-CRP [62]. Whereas another study failed to show a significant association between obesity and hs-CRP in 192 Iranian adults [63]. This disparity in results may be due to the different sample size. FFAs are drained by the liver which leads to secret pro-inflammatory adipokines into the portal circulation and promotes interlukine-6 (IL-6) releasing from adipose tissue, which finally results in the secretion of CRP [64, 65]. IL-6 is a mediator of inflammatory process which produces by immune cells and adipose tissue [66]. The high concentrations of IL-6 leads to endothelial/microvascular dysfunction, as well as overproduction of ROS which finally increases the concentrations of systemic CRP [67]. It is reported that each degree of obesity was directly correlated with CRP [68]. As a study on women in Montenegro, the levels of CRP in over-weight women was higher than the normal weight group [69]. According to a study on Indian children, by increasing 1.0 unit of BMI, CRP odds ratios increased by nearly 40% (p < 0.001, 95% CI: 1.23–1.53) [70].

Aside from the underlying population-based large scale research’s strengths, a number of limitations need to be noted regarding the current study. First, only participants aged between 35 and 65 years old were evaluated in this study. Second, it is a cross-sectional study, so no causal association could be identified. Third, we have not access to the medications, supplementation, or alcohol history of the participants, so we could not remove the effect of these confounders.

Conclusion

Generally, this study shows the association between obesity and inflammation and oxidative stress. Understanding of the obesity-associated conditions would be helpful in order to develop new treatments, and for preventing several disorders. Future studies should characterize the potential mechanisms and roles of oxidative stress and inflammation in obesity to control the onset and deterioration of autoimmune and/or inflammatory diseases.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

BMI:

Body mass index

CV:

Coefficients of variation

CVDs:

Cardiovascular diseases

DBP:

Diastolic blood pressure

FBG:

Fasting blood glucose

FFAs:

Free fatty acids

GPx:

Glutathione peroxidase

HDL-C:

High-density lipoprotein cholesterol

hs-CRP:

High sensitive C-reactive protein

IL-6:

Interlukine-6

LDL-C:

Low-density lipoprotein cholesterol

MASHAD:

Mashhad Stroke and Heart Atherosclerotic Disorder

PAB:

Pro-oxidant-antioxidant balance

PAL:

Physical activity level

ROS:

Reactive oxygen species

SBP:

Systolic blood pressure

SOD1 :

Superoxide dismutase type 1

TBARS:

Thiobarbituric acid reactive substances

TG:

Triglycerides

References

  1. Ghazizadeh H, Mirinezhad SMR, Asadi Z, Parizadeh SM, Zare-Feyzabadi R, Shabani N, Eidi M, Mosa Farkhany E, Esmaily H, Mahmoudi AA. Association between obesity categories with cardiovascular disease and its related risk factors in the MASHAD cohort study population. J Clin Lab Anal. 2020;34(5):e23160.

    Article  CAS  PubMed  Google Scholar 

  2. Saxton SN, Clark BJ, Withers SB, Eringa EC, Heagerty AM. Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue. Physiol Rev. 2019;99(4):1701–63.

    Article  CAS  PubMed  Google Scholar 

  3. Saberi-Karimian M, Mansoori A, Bajgiran MM, Hosseini ZS, Kiyoumarsioskouei A, Rad ES, Zo MM, Khorasani NY, Poudineh M, Ghazizadeh S. Data mining approaches for type 2 diabetes mellitus prediction using anthropometric measurements. J Clin Lab Anal. 2023;37(1):e24798.

    Article  CAS  PubMed  Google Scholar 

  4. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35.

    Article  CAS  PubMed  Google Scholar 

  5. Mansoori A, Hosseini ZS, Ahari RK, Poudineh M, Rad ES, Zo MM, Izadi FS, Hoseinpour M, Miralizadeh A, Mashhadi YA. Development of data mining algorithms for identifying the best anthropometric predictors for cardiovascular disease: MASHAD cohort study. High Blood Press Cardiovasc Prev. 2023;30(3):243–53.

    Article  PubMed  Google Scholar 

  6. WHO. Obesity and overweight. 2021.

  7. Abiri B, Ahmadi AR, Amini S, Akbari M, Hosseinpanah F, Madinehzad SA, Hejazi M, Rishehri AP, Naserghandi A, Valizadeh M. Prevalence of overweight and obesity among Iranian population: a systematic review and meta-analysis. J Health Popul Nutr. 2023;42(1):70.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Reviews Endocrinol. 2019;15(5):288–98.

    Article  Google Scholar 

  9. Ghazizadeh H, Rezaei M, Avan A, Fazilati M, Pasdar A, Tavallaie S, Kazemi E, Seyedi SMR, Ferns GA, Azimi-Nezhad M. Association between serum cell adhesion molecules with hs-CRP, uric acid and VEGF genetic polymorphisms in subjects with metabolic syndrome. Mol Biol Rep. 2020;47(2):867–75.

    Article  CAS  PubMed  Google Scholar 

  10. Schnurr TM, Jakupović H, Carrasquilla GD, Ängquist L, Grarup N, Sørensen TI, Tjønneland A, Overvad K, Pedersen O, Hansen T. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. Diabetologia. 2020;63(7):1324–32.

    Article  CAS  PubMed  Google Scholar 

  11. Kazemi E, Zargooshi J, Kaboudi M, Heidari P, Kahrizi D, Mahaki B, Mohammadian Y, Khazaei H, Ahmed K. A genome-wide association study to identify candidate genes for erectile dysfunction. Brief Bioinform. 2020.

  12. Mohammadi A, Sahebkar A, Kermani T, Zhilaee M, Tavallaie S, Mobarhan MG. Barberry administration and pro-oxidant–antioxidant balance in patients with metabolic syndrome. Iran Red Crescent Med J. 2014;16(12).

  13. Ghazizadeh H, Mirinezhad MR, Seyedi SMR, Sadabadi F, Ahmadnezhad M, Jaberi N, Pasdar A, Ferns GA, Esmaily H, Ghayour-Mobarhan M. Prognostic factors associating with pro-oxidant-antioxidant balance; neutrophils to lymphocytes ratio, vitamin D, heat shock protein 27, and red cell distribution width. Arch Med Res. 2020;51(3):261–7.

    Article  CAS  PubMed  Google Scholar 

  14. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18(6):655–73.

    Article  CAS  PubMed  Google Scholar 

  15. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J. 2012;12(1):5.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sahiner UM, Birben E, Erzurum S, Sackesen C, Kalayci O. Oxidative stress in asthma. World Allergy Organ J. 2011;4(10):151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Patel C, Ghanim H, Ravishankar S, Sia CL, Viswanathan P, Mohanty P, Dandona P. Prolonged reactive oxygen species generation and nuclear factor-κB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metabolism. 2007;92(11):4476–9.

    Article  CAS  Google Scholar 

  18. Ozata M, Mergen M, Oktenli C, Aydin A, Sanisoglu SY, Bolu E, Yilmaz MI, Sayal A, Isimer A, Ozdemir IC. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem. 2002;35(8):627–31.

    Article  CAS  PubMed  Google Scholar 

  19. Cobos-Palacios L, Ruiz-Moreno MI, Vilches-Perez A, Vargas-Candela A, Muñoz-Úbeda M, Benítez Porres J. Metabolically healthy obesity: inflammatory biomarkers and adipokines in elderly population. 2022;17(6):e0265362.

  20. Pavela G, Kim YI, Salvy SJ. Additive effects of obesity and loneliness on C-reactive protein. 2018;13(11):e0206092.

  21. Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Design. 2005;11(32):4145–51.

    Article  CAS  Google Scholar 

  22. Fabbrini E, Serafini M, Baric IC, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2013:DB_131396.

  23. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. P Natl Acad Sci. 1981;78(11):6858–6862.

  24. Duan Y, Liang W, Zhu L, Zhang T, Wang L, Nie Z, Chen Y, He L, Jin Y, Yao Y. Association between serum uric acid levels and obesity among university students (China). Nutr Hosp. 2015;31(6).

  25. Oyama C, Takahashi T, Oyamada M, Oyamada T, Ohno T, Miyashita M, Saito S, Komatsu K, Takashina K, Takada G. Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med. 2006;209(3):257–62.

    Article  CAS  PubMed  Google Scholar 

  26. Chen M-Y, Zhao C-C, Li T-T, Zhu Y, Yu T-P, Bao Y-Q, Li L-X, Jia W-P. Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. Sci Rep. 2017;7:40009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, Safarian M, Mokhber N, Nematy M, Saber H. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561–72.

    Article  PubMed  Google Scholar 

  28. Weir CB, Jan A. BMI classification percentile and cut off points. 2019.

  29. Norton K. Measurement techniques in anthropometry. Antropometrica. 1996.

  30. Vasconcellos M, Anjos L. A simplified method for assessing physical activity level values for a country or study population. Eur J Clin Nutr. 2003;57(8):1025.

    Article  CAS  PubMed  Google Scholar 

  31. Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M, Meshkat Z, Mehrad-Majd H, Eslami S, Rahimi HR. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr. 2015;113(12):1911–9.

    Article  CAS  PubMed  Google Scholar 

  32. Mirhafez SR, Mohebati M, Disfani MF, Karimian MS, Ebrahimi M, Avan A, Eslami S, Pasdar A, Rooki H, Esmaeili H. An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension. J Am Soc Hypertens. 2014;8(9):614–23.

    Article  CAS  PubMed  Google Scholar 

  33. Rahsepar AA, Pourghadamyari H, Moohebati M, Parizadeh SMR, Tavallaie S, Paydar R, Falsoleiman H, Dehghani M, Fazlinezhad A, Amini M. Prooxidant–anti-oxidant balance is not associated with extent of coronary artery disease. Clin Biochem. 2011;44(16):1304–8.

    Article  CAS  PubMed  Google Scholar 

  34. Alamdari DH, Ghayour-Mobarhan M, Tavallaie S, Parizadeh MR, Moohebati M, Ghafoori F, Kazemi-Bajestani SMR, Paletas K, Pegiou T, Koliakos G. Prooxidant–antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem. 2008;41(6):375–80.

    Article  CAS  PubMed  Google Scholar 

  35. Ghayour-Mobarhan M, Alamdari DH, Moohebati M, Sahebkar A, Nematy M, Safarian M, Azimi-Nezhad M, Reza Parizadeh SM, Tavallaie S, Koliakos G. Determination of prooxidant—antioxidant balance after acute coronary syndrome using a rapid assay: a pilot study. Angiology. 2009;60(6):657–62.

    Article  CAS  PubMed  Google Scholar 

  36. Ahmadnezhad M, Arefhosseini SR, Parizadeh MR, Tavallaie S, Tayefi M, Darroudi S, Ghazizadeh H, Moohebati M, Ebrahimi M, Heidari-Bakavoli A. Association between serum uric acid, high sensitive C‐reactive protein and pro‐oxidant‐antioxidant balance in patients with metabolic syndrome. BioFactors. 2018;44(3):263–71.

    Article  CAS  PubMed  Google Scholar 

  37. Ghazizadeh H, Kathryn Bohn M, Ghaffarian Zirak R, Kamel Khodabandeh A, Zare-Feyzabadi R, Saberi‐Karimian M, Timar A, Jaberi N, Mohammadi‐Bajgiran M, Sharifan P. Comprehensive laboratory reference intervals for routine biochemical markers and pro‐oxidant‐antioxidant balance (PAB) in male adults. J Clin Lab Anal. 2020;34(11):e23470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rahmanian M, Kelishadi R, Qorbani M, Motlagh ME, Shafiee G, Aminaee T, Ardalan G, Taslimi M, Poursafa P, Asayesh H. Dual burden of body weight among Iranian children and adolescents in 2003 and 2010: the CASPIAN-III study. Archives Med Science: AMS. 2014;10(1):96.

    Article  PubMed Central  Google Scholar 

  39. Darroudi S, Fereydouni N, Tayefi M, Ahmadnezhad M, Zamani P, Tayefi B, Kharazmi J, Tavalaie S, Heidari-Bakavoli A, Azarpajouh MR. Oxidative stress and inflammation, two features associated with a high percentage body fat, and that may lead to diabetes mellitus and metabolic syndrome. BioFactors. 2019;45(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  40. Lee H, Lee YJ, Choi H, Ko EH, Kim J-w. Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem. 2009;284(16):10601–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tormos KV, Anso E, Hamanaka RB, Eisenbart J, Joseph J, Kalyanaraman B, Chandel NS. Mitochondrial complex III ROS regulate adipocyte differentiation. Cell Metabol. 2011;14(4):537–44.

    Article  CAS  Google Scholar 

  42. Wagner G, Lindroos-Christensen J, Einwallner E, Husa J, Zapf T-C, Lipp K, Rauscher S, Gröger M, Spittler A, Loewe R. HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2. Sci Rep. 2017;7:40881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C. Morales-González JA: Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5):3117–3132.

  44. McMurray F, Patten DA, Harper ME. Reactive oxygen species and oxidative stress in obesity—recent findings and empirical approaches. Obesity. 2016;24(11):2301–10.

    Article  CAS  PubMed  Google Scholar 

  45. Lefranc C, Friederich-Persson M, Palacios-Ramirez R, Cat AND. Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor. J Endocrinol. 2018;238(3):R143–59.

    Article  CAS  PubMed  Google Scholar 

  46. Avval FZ, Mahmoudi N, Tirkani AN, Jarahi L, Alamdari DH, Sadjadi SA. Determining pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in patients with schizophrenia. Iran J Psychiatry. 2018;13(3):222.

    Google Scholar 

  47. Razavi A, Baghshani MR, Ardabili HM, Andalibi M, Rahsepar AA, Moohebati M, Nematy M, Tavallaie S, Mousavi S, Akhlaghi S. Obese subjects have significantly higher serum prooxidantantioxidant balance values compared to normal-weight subjects. Clin Lab. 2013;59(3–4):257–61.

    CAS  PubMed  Google Scholar 

  48. Nikrad N, Shakarami A, Rahimi Z, Janghorbanian-Poodeh R, Farhangi MA, Hosseini B, Jafarzadeh F. Dietary pro-oxidant score (POS) and cardio-metabolic panel among obese individuals: a cross-sectional study. BMC Endocr Disorders. 2023;23(1):144.

    Article  CAS  Google Scholar 

  49. Razavi A, Baghshani MR, Ardabili HM, Andalibi MS, Rahsepar AA, Moohebati M, Nematy M, Tavallaie S, Mousavi S, Akhlaghi S, et al. Obese subjects have significantly higher serum prooxidantantioxidant balance values compared to normal-weight subjects. Clin Lab. 2013;59(3–4):257–61.

    CAS  PubMed  Google Scholar 

  50. Noruzi Z, Jayedi A, Farazi M, Asgari E, Dehghani Firouzabadi F, Akbarzadeh Z, Djafarian K, Shab-Bidar S. Association of oxidative balance score with the metabolic syndrome in a sample of Iranian adults. Oxid Med Cell Longev. 2021;2021.

  51. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig. 2017;114(12):1752–61.

    Article  Google Scholar 

  52. Darroudi S, Tajbakhsh A, Esmaily H, Ghazizadeh H, Zamani P, Sadabadi F, Tayefi M, Tayefi B, Fereydouni N, Mouhebati M. 50 bp deletion in promoter superoxide dismutase 1 gene and increasing risk of cardiovascular disease in Mashhad stroke and heart atherosclerotic disorder cohort study. BioFactors. 2020;46(1):55–63.

    Article  CAS  PubMed  Google Scholar 

  53. Wassmann S, Wassmann K, Nickenig G. Regulation of antioxidant and oxidant enzymes in vascular cells and implications for vascular disease. Curr Hypertens Rep. 2006;8(1):69–78.

    Article  CAS  PubMed  Google Scholar 

  54. Lewandowski Ł, Kepinska M, Milnerowicz H. Alterations in concentration/activity of superoxide dismutases in context of obesity and selected single nucleotide polymorphisms in genes: SOD1, SOD2, SOD3. Int J Mol Sci. 2020;21(14):5069.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Mahdavi-Roshan M, Movahedian M, Varkaneh HK, Salari A, Macit MS, Rezazadeh A. Association of uric acid with metabolic parameters and obesity. Nutr Food Sci. 2020;50(6):1241–54.

    Article  Google Scholar 

  56. Honggang W, Lizhen W, Rui X, Weijie D, Chengcheng G, Peng S, Xiaodan HUANGFZ, Xiaozhong Y, Guozhong J. Association of serum uric acid with body mass index: a cross-sectional study from Jiangsu Province, China. Iran J Public Health. 2014;43(11):1503.

    Google Scholar 

  57. Rathmann W, Haastert B, Icks A, Giani G, Roseman JM. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol. 2007;22(7):439–45.

    Article  CAS  PubMed  Google Scholar 

  58. Chen L-y, Zhu W-h, Chen Z-w, Dai H-l, Ren J-j, Chen J-h. Chen L-q, Fang L-z: relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18(1):81.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Tang J, Liu K, Eshak ES, Cui R, Sakaniwa R, Imano H, Dong JY, Iso H. Association between serum uric acid and impaired endothelial function: the circulatory risk in communities study. J Atheroscler Thromb. 2022;29(10):1534–46.

    Article  CAS  PubMed  Google Scholar 

  61. 홍은별. The mechanism of macrophage activation by down-regulation of fatty acid synthase in obesity. 서울대학교 융합과학기술대학원; 2016.

  62. Ebrahimi M, Heidari-Bakavoli AR, Shoeibi S, Mirhafez SR, Moohebati M, Esmaily H, Ghazavi H, Saberi Karimian M, Parizadeh SMR, Mohammadi M. Association of serum hs‐CRP levels with the presence of obesity, diabetes mellitus, and other cardiovascular risk factors. J Clin Lab Anal. 2016;30(5):672–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mirhoseini M, Daemi H, Babaiee MM, Asadi-Samani M, Mirhoseini L, Sedehi M. Serum concentration of hs-CRP in obese individuals with and without metabolic syndrome and its association with parameters of metabolic syndrome. J Ren Injury Prev. 2018;7(4):297–300.

    Article  CAS  Google Scholar 

  64. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860.

    Article  CAS  PubMed  Google Scholar 

  65. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010;106(1):56–61.

    Article  CAS  PubMed  Google Scholar 

  66. West NR. Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front Immunol. 2019;10:1093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Archives Med Science: AMS. 2017;13(4):851.

    Article  CAS  Google Scholar 

  68. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta‐analysis. Obes Rev. 2013;14(3):232–44.

    Article  CAS  PubMed  Google Scholar 

  69. Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragón-Alonso A, Pascual-Díaz M, Pérez-Paredes M, Lozano-Almela ML. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.

    Article  PubMed  Google Scholar 

  70. RiganÒ R, Profumo E, Buttari B, Tagliani A, Petrone L, D’amati G, Ippoliti F, Capoano R, Fumagalli L, Salvati B. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann N Y Acad Sci. 2007;1107(1):1–10.

    Article  PubMed  Google Scholar 

  71. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

    Article  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the contributions of the data collection team and the individuals who participated in this study.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. CALIPER Program, Division of Clinical Biochemistry, Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada

    Hamideh Ghazizadeh

  2. Department of Applied Mathematics, School of Mathematical Sciences, Ferdowsi University of Mashhad, Mashhad, Iran

    Amin Mansoori

  3. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Toktam Sahranavard & Mohamad Nasrabadi

  4. Student Research Committee, School of Medicine, Zanjan University in Medical Science, Zanjan, Iran

    Kaveh Hadiloo

  5. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Nazanin Sheikh Andalibi, Ameneh Timar & Majid Ghayour-Mobarhan

  6. Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Marzyeh Azmon

  7. Department of Biochemistry and Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Shima Tavallaei

  8. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK

    Gordon A Ferns

Authors
  1. Hamideh Ghazizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amin Mansoori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toktam Sahranavard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamad Nasrabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaveh Hadiloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nazanin Sheikh Andalibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marzyeh Azmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shima Tavallaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ameneh Timar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gordon A Ferns
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Majid Ghayour-Mobarhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HG, AM and TS wrote the paper. AM and MN analyzed data. KH, NSh, ST, MA, and AT conducted the research. GAF and MGh designed research. MGh had primary responsibility for final content. All authors have read and approved the final manuscript.

Corresponding authors

Correspondence to Amin Mansoori or Majid Ghayour-Mobarhan.

Ethics declarations

Ethics approval and consent to participate

The Human Research Ethics Committee of Mashhad University of Medical Sciences (MUMS) evaluated and approved the study (IR.MUMS.REC.1386.250). All participants provided written informed consent. All research methods were conducted in accordance with the World Medical Association Declaration of Helsinki ethical standards for medical research [71].

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghazizadeh, H., Mansoori, A., Sahranavard, T. et al. The associations of oxidative stress and inflammatory markers with obesity in Iranian population: MASHAD cohort study. BMC Endocr Disord 24, 56 (2024). https://doi.org/10.1186/s12902-024-01590-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-024-01590-9

Keywords

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us